Full-Time

Regional Nurse Educator

Posted on 10/31/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Remote in Canada

Hybrid

Category
Medical, Clinical & Veterinary (2)
,
Requirements
  • Qualified registered nurse in the province of residence (valid provincial license from the College of Nurses)
  • Healthcare provider CPR certificate required
  • Minimum 5 years’ experience as a Registered Nurse with experience being a nurse educator, clinical resource to other health care professionals
  • 3 years of regular IV initiation and infusion experience
  • ACLS, CVAA Certification, and central venous line/port experience are required
  • Possess a valid driver’s license, access to a reliable vehicle, and car insurance
Responsibilities
  • Accountable for creation and ongoing development of training standards, documents, policies and processes for any new initiatives in collaboration with Nursing leadership
  • Acts as a resource for all Field Nurses and BAMs to grow in proficiency and confidence regarding molecule specific standard operating procedures, work instructions and disease state understanding by providing clinical guidance to Field Nurses to make the adoption of new knowledge, information and best practices integrated into real time patient care delivery with a focus on PSPs and ICP
  • Participates regularly in telephone consultations and/or web based meetings/training sessions with Field Nurses within their geographical area or across Canada
  • Develops expert knowledge on the administration of biologics, specialty biologics, biosimilars and specialty generic drugs by actively participating in all launch and client-provided education seminars as well as self-directed study, with a focus on disease state and clinical skill
  • On a quarterly basis, collaborates with designated BAM/IBU to assess training needs specific to that IBU/region and/or nationally across Canada, and then creates and delivers training, including remedial training plans or re-training of nurses returning from leave
  • In collaboration with the Nursing Leadership team, develops and implements patient education tools, nursing educational materials, nursing competency assessment tools, evaluation tools and critical thinking case studies reflecting evidence informed practices that support remote learning
  • Works collaboratively with other Regional Nurse Educators and Business Area Managers to support Innomar’s Field Nurse Preceptorship program by providing tools and training to new Preceptors, participating in the selection of nurses for preceptor roles
  • Responsible for the design and ongoing development of competency requirements for Innomar’s Field Nurse Preceptorship program, in collaboration with Business Area Managers, and contributes to the ongoing evaluation of preceptors in their role
  • Works collaboratively with peers and other departments to ensure efficiencies are realized with product and disease state training for each new molecule launch, including decision-making for cost-effective nursing supplies and practices
  • Drives standardization of nursing practice and processes through ongoing research into best practices, and takes leadership in the development of nursing Policies, Standard Operating Procedures, Work Instructions and Forms
  • Takes leadership in creation of Quality and Best Practice cross-functional committees, terms of reference and agendas to support interdisciplinary collaboration and decision-making on best nursing practices for Innomar
  • Works collaboratively with other Regional Nurse Educators and Business Area Managers to review CAPAs, attend or review audits, review incident reports and patient complaints to determine training gaps and recommend practice solutions
  • In collaboration with the BAM, participates remotely in recruitment interviews of Field Nurses, providing input into skills assessments and learning plans
  • Attends therapeutic area conferences based on business needs, and presents at conferences based on subject matter expertise, as appropriate
  • In partnership with DNOs and BAMs, supports KOLs and drives Innomar’s brand presence through delivery of patient education to their therapeutic patient groups, based on own subject matter expertise
  • Acts as a resource to clients to support new initiatives or fill training gaps identified by the client
  • Acts as the face of the organization through appearance, attitude, and communication when in client and professional settings, such as conferences, train the trainer sessions, and meetings with KOLs etc. Monitors updates within provincial legislations, clinical requirements and industry trends Actively participates in Nursing team and interdepartmental meetings
  • At times may be called upon to consult with physicians, pharmaceutical and biotechnology clients regarding education and implementation of product specific programs
  • Flexibility in order to provide services for pre-scheduled meetings, training sessions, mentorship/support activities, and occasional last-minute requests, in-person, via teleconference, when required be available to travel to attend in-person Innomar office meetings and other meeting locations.
  • Adheres to professional nursing standards as prescribed by the professional associations and the company
  • Develops and demonstrates expanding expertise in all therapeutic areas of interest to Innomar
  • Performs related duties and tasks as required
  • May be required to be on standby/ on call as part of this role
Desired Qualifications
  • Masters' education is preferred
  • Oncology experiences an asset
  • Experience with research an asset
  • member of a nursing association preferred
  • Comfort with working on online platforms and virtual teaching
  • Teaching experience preferred

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty pharmaceuticals remain the main growth engine for higher-margin services.
  • Management targets $300 million in savings while sustaining about $3 billion free cash flow.
  • Share repurchases and accretive acquisitions can support earnings per share.

What critics are saying

  • Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
  • Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
  • Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.

What makes Cencora unique

  • Cencora combines drug distribution, specialty pharmacy, and patient-support services.
  • It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
  • The company is expanding specialty care through OneOncology and EyeSouth retina assets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE